Late Recurrence in Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 4976
Special Issue Editor
Interests: breast cancer; HER2; cancer biomarkers; tumors: cancers; post-translational modifications; ubiquitination; thyroid cancer; ubiquitin
Special Issue Information
Dear Colleagues,
The majority of breast cancer (BC) metastasis does not appear at the same time as the primary tumor, and the time to recurrence varies considerably. Late recurrence, which occurs five or more years after the initial primary diagnosis, indicates a long dormant period of undetectable metastases, which therefore presents a significant clinical challenge for BC. Roughly 20–40% of estrogen receptor (ER)-positive BC patients eventually develop distant metastasis, and half of them correspond to late recurrence. Accurate and reliable estimates of the risk of late recurrence would enable appropriate management.
We invite authors to submit their original or review work to the Special Issue entitled “Late Recurrence in Breast Cancer" as it relates to late recurrence in tumor biology with a focus on the following:
- Recurrence dynamics;
- Tumor dormancy;
- Dormancy cancer cell reactivation;
- Biomarkers for detecting breast cancer patients with late recurrence;
- Cancer stem cells;
- Genomic profiles;
- Tumor microenvironment;
- Novel targets in dormancy cancer cells.
I look forward to receiving your contributions.
Dr. Takashi Takeshita
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- late recurrence
- recurrence dynamics
- tumor dormancy
- dormancy cancer cell reactivation
- cancer stem cells
- genomic profiles
- tumor microenvironment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
